CMR与MPS-SPECT诊断冠状动脉疾病的成本效益:近期趋势的系统综述
系统综述比较CMR与MPS-SPECT在低至中等CAD概率患者中的成本效益,发现CMR更具成本效益。
基本信息
资源简介
CMR与MPS-SPECT诊断冠状动脉疾病的成本效益:近期趋势的系统综述
【数据集背景】
本数据集源站标题为《Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD》,为 CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD 的组成部分。配套论文《Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD》发表于 Journal of Medical Economics(2025),DOI:10.1080/13696998.2025.2550331。源站首次发布:2025-09-10。
【数据内容】
源站原始描述:The health economic impacts of cardiovascular magnetic resonance (CMR) imaging and myocardial perfusion scintigraphy by single photon emission computed tomography (MPS-SPECT) as diagnostic modalities are not well understood. This review is based on a wider systematic review and aims to compare CMR and MPS-SPECT as first-line, non-invasive modalities for the diagnosis of symptomatic individuals with a low-to-intermediate pre-test probability (PTP) of coronary artery disease (CAD). We performed a…
【数据结构与技术规格】
文件数 3 个,合计 362.53 KB。ijme_a_2550331_sm0154.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,283.56 KB。ijme_a_2550331_sm5662.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,31.16 KB。ijme_a_2550331_sm5656.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,47.81 KB。数据集 DOI:10.6084/m9.figshare.29959378.v2。
【主题与分类】
源站学科分类:Medicine、Science Policy。主题标签:Coronary artery disease、ischemic heart disease、cardiovascular magnetic resonance、myocardial perfusion scintigraphy by single photon emission computed tomography、health economic analysis、cost-effectiveness、I10、I19。
【适用方向】
文本类数据可用于医学自然语言处理,如命名实体识别、信息抽取与文本分类。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/Cost_effectiveness_of_CMR_over_MPS-SPECT_a_systematic_review_of_recent_trends_for_diagnosing_CAD/29959378
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD. Taylor & Francis. Kluge, Ben; Harris, James; Sánchez-Collado, Irene; Pérez-Román, Inés; Paffett, Molly; Christophel, Sina; et al
【使用注意】
· 源站最后修改于 2026-01-21,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD
- DOI:10.6084/m9.figshare.29959378.v2
- 发布日期:2025-09-10
- 文件数:3 个
- 文件总体积:362.53 KB
- 源站页面:https://tandf.figshare.com/articles/dataset/Cost_effectiveness_of_CMR_over_MPS-SPECT_a_systematic_review_of_recent_trends_for_diagnosing_CAD/29959378
命令行下载
curl -L -o "ijme_a_2550331_sm0154.docx" "https://ndownloader.figshare.com/files/57829423"
curl -L -o "ijme_a_2550331_sm5662.docx" "https://ndownloader.figshare.com/files/57829426"
curl -L -o "ijme_a_2550331_sm5656.docx" "https://ndownloader.figshare.com/files/57829429"
文件清单
ijme_a_2550331_sm0154.docx(283.56 KB)ijme_a_2550331_sm5662.docx(31.16 KB)ijme_a_2550331_sm5656.docx(47.81 KB)
文件总体积 362.53 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
The health economic impacts of cardiovascular magnetic resonance (CMR) imaging and myocardial perfusion scintigraphy by single photon emission computed tomography (MPS-SPECT) as diagnostic modalities are not well understood. This review is based on a wider systematic review and aims to compare CMR and MPS-SPECT as first-line, non-invasive modalities for the diagnosis of symptomatic individuals with a low-to-intermediate pre-test probability (PTP) of coronary artery disease (CAD).
We performed a systematic review of MEDLINE and Embase, MEDLINE In-process, the Cochrane Database of Systematic reviews and the Cochrane Central Register of Controlled Trials. Studies from January 1992 to January 2023 were included, if they were based in the UK, France, Germany, Italy, Japan, China, and/or the USA (published in any language). Risk of bias was assessed using the Drummond checklist.
Thirteen relevant reports were identified. In the USA, CMR was consistently cost-effective compared with MPS-SPECT for patients with a low-to-intermediate PTP of CAD; resource use and associated costs, as well as total costs, were lower. For patients with a low-to-intermediate PTP of CAD in Europe, CMR was cost-effective in Germany, while in the UK increases in quality-adjusted life-years were found but cost savings were mixed. This review found only 13 reports on the economic benefits of CMR over MPS-SPECT, with just three providing cost-effectiveness outcomes, highlighting the need for further research across different settings and perspectives.
Overall, findings suggest that the cost savings from using CMR compared with MPS-SPECT for patients with a low-to-intermediate PTP of CAD support prioritized investment; however, confirmatory research is needed given the limited number of cost-effectiveness analyses identified in this review.
Imaging of the heart and its blood vessels is typically used to diagnose coronary artery disease. Non-invasive tests have improved recently. Therefore, doctors are finding them more useful. Global clinical guidelines generally recommend that the choice of imaging test is based on whether patients have a low, intermediate, or high chance of having the disease
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.29959378.v2(source: https://tandf.figshare.com/articles/dataset/Cost_effectiveness_of_CMR_over_MPS-SPECT_a_systematic_review_of_recent_trends_for_diagnosing_CAD/29959378)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




